Table 1.

Comparison of amyloid-lowering monoclonal antibodies based on phase III data (except donanemab which currently only has phase II data)

	Aducanumab	Lecanemab	Donanemab
Cognitive slowing on primary outcome measure (%)	22	27	32
Amyloid removal as measured by PET SUVr (%)	70	77	80
ARIA incidence rates (%)	33	13	28

ARIA amyloid-related imaging abnormalities, PET positron emission tomography, SUVr standardized uptake value ratio